Abstract:BACKGROUND:Polycystic ovary syndrome (PCOS) is associated with increased metabolic risk, though data on long-term follow-up of cardiometabolic traits are limited. We postulated that Chinese women with PCOS would have higher risk of incident diabetes and cardiometabolic abnormalities than those without PCOS during long-term follow-up. METHODS AND FINDINGS:One hundred ninety-nine Chinese women with PCOS diagnosed by the Rotterdam criteria and with a mean age of 41.2 years (SD = 6.4) completed a follow-up evaluation after an average of 10.6 ± 1.3 years. Two hundred twenty-five women without PCOS (mean age: 54.1 ± 6.7 years) who underwent baseline and follow-up evaluation over the same period were used for comparison. Progression of glycaemic status of women both with and without PCOS was assessed by using 75-g oral glucose tolerance test (OGTT) screening with the adoption of 2009 American Diabetes Association diagnostic criteria. The frequency of impaired glucose regulation, hypertension, and hyperlipidaemia of women with PCOS at follow-up has increased from 31.7% (95% CI 25.2%-38.1%) to 47.2% (95% CI 40.3%-54.2%), 16.1% (95% CI 11.0%-21.2%) to 34.7% (95% CI 28.1%-41.3%), and 52.3% (95% CI 45.3%-59.2%) to 64.3% (95% CI 57.7%-71.0%), respectively. The cumulative incidence of diabetes mellitus (DM) in follow-up women with PCOS is 26.1% (95% CI 20.0%-32.2%), almost double that in the cohort of women without PCOS (p < 0.001). Age-standardised incidence of diabetes among women with PCOS was 22.12 per 1,000 person-years (95% CI 10.86-33.37) compared with the local female population incidence rate of 8.76 per 1,000 person-years (95% CI 8.72-8.80) and 10.09 per 1,000 person-years (95% CI 4.92-15.26, p < 0.001) for women without PCOS in our study. Incidence rate for women with PCOS aged 30-39 years was 20.56 per 1,000 person-years (95% CI 12.57-31.87), which is approximately 10-fold higher than that of the age-matched general female population in Hong Kong (1.88 per 1,000 person-years, [95% CI 1.85-1.92]). The incidence rate of type 2 DM (T2DM) of both normal-weight and overweight women with PCOS was around double that of corresponding control groups (normal weight: 8.96 [95% CI 3.92-17.72] versus 4.86 per 1,000 person-years [95% CI 2.13-9.62], p > 0.05; overweight/obese: 28.64 [95% CI 19.55-40.60] versus 14.1 per 1,000 person-years [95% CI 8.20-22.76], p < 0.05). Logistic regression analysis identified that baseline waist-to-hip ratio (odds ratio [OR] = 1.71 [95% CI 1.08-2.69], p < 0.05) and elevated triglyceride (OR = 6.63 [95% CI 1.23-35.69], p < 0.05) are associated with the progression to T2DM in PCOS. Limitations of this study include moderate sample size with limited number of incident diabetes during follow-up period and potential selection bias. CONCLUSIONS:High risk of diabetes and increased cardiovascular disease risk factors among Chinese women with PCOS are highlighted in this long-term follow-up study. Diabetes onset was, on average, 10 years earlier among women with PCOS than in women without PCOS.

Relationship between cardiometabolic index and early phase β-cell function in overweight or obese patients with polycystic ovarian syndrome

Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis

Insulin resistance and β-cell dysfunction and the relationship with cardio-metabolic disorders among women with polycystic ovary syndrome

Relationship between body composition, insulin resistance, and hormonal profiles in women with polycystic ovary syndrome

To Assess the Association between Glucose Metabolism and Ectopic Lipid Content in Different Clinical Classifications of PCOS

Association of Serum Thyroid Hormone Levels with Androgen and Metabolic Parameters in Chinese Women with Polycystic Ovary Syndrome: A Retrospective Cross-Sectional Study

Metabolic Deregulations in Patients with Polycystic Ovary Syndrome

Insulin resistance and its correlation with body composition in patients with obese polycystic ovary syndrome

Association Between Vitamin D and Metabolic Indexes in Patients with Polycystic Ovary Syndrome

Clinical phenotype and endocrine metabolic parameters in polycystic ovary syndrome patients with and without hyperandrogenemia

Metabolic Characteristics of Normal Weight Central Obesity Phenotype Polycystic Ovary Syndrome Women: a Large-Scale National Epidemiological Survey.

Association of severity of menstrual dysfunction with cardiometabolic risk markers among women with polycystic ovary syndrome

Relationship between hyperandrogen and impaired glucose regulation in women with polycystic ovary syndrome

Metabolic characteristics of polycystic ovary syndrome patients with different body mass index and clinical phenotypes

Dyslipidemia in Relation to Body Mass Index and Insulin Resistance in Chinese Women with Polycystic Ovary Syndrome.

Serum Anti-Müllerian Hormone and Insulin Resistance in the Main Phenotypes of Non-Obese Polycystic Ovarian Syndrome Women in China.

Characteristics and possible mechanisms of metabolic disorder in overweight women with polycystic ovary syndrome

Insulin resistance and endocrine-metabolic abnormalities in polycystic ovarian syndrome: Comparison between obese and non-obese PCOS patients

Analysis of endocrine and metabolic characteristics in patients with polycystic ovary syndrome in Beijing

Insulin resistance and high molecular weight adiponectin in obese and non-obese patients with Polycystic Ovarian Syndrome (PCOS)

Progression of Glucose Intolerance and Cardiometabolic Risk Factors over a Decade in Chinese Women with Polycystic Ovary Syndrome: A Case-Control Study.